Biotech · Public company · South San Francisco, CA, US
Vistagen Therapeutics, Inc.
Ticker VTGN · SEC CIK 0001411685
Track this companyFree. Adds Vistagen Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials100 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline9
- Fasedienol Nasal SprayPhase 3 · Social Anxiety DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Fasedienol Nasal SprayPhase 3 · Social Anxiety Disorder (SAD)ClinicalTrials.gov · fetched Nov 12, 2026
- PH94BPhase 3 · Social Anxiety DisorderClinicalTrials.gov · fetched Nov 12, 2026
- PH94B Nasal SprayPhase 3 · Social Anxiety DisorderClinicalTrials.gov · fetched Nov 12, 2026
- AV-101Phase 2 · Major Depressive DisorderClinicalTrials.gov · fetched Nov 12, 2026
- Fasedienol Nasal Spray - Fasedienol Nasal SprayPhase 2 · Social Anxiety DisorderClinicalTrials.gov · fetched Nov 12, 2026
- PH94BPhase 2 · Adjustment Disorder With Anxious MoodClinicalTrials.gov · fetched Nov 12, 2026
- AV-101Phase 1 · Drug Drug InteractionClinicalTrials.gov · fetched Nov 12, 2026
- ProbenecidPhase 1 · Drug Drug InteractionClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety DisorderPHASE2 · COMPLETED · started Jan 9, 2025ClinicalTrials.gov NCT06809179 · fetched Nov 12, 2026
- Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)PHASE3 · COMPLETED · started Sep 16, 2024ClinicalTrials.gov NCT06615557 · fetched Nov 12, 2026
- Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)PHASE3 · COMPLETED · started Mar 28, 2024ClinicalTrials.gov NCT06358651 · fetched Nov 12, 2026
- AV-101 Alone and in Combination With Probenecid in Healthy SubjectsPHASE1 · UNKNOWN · started Dec 23, 2021ClinicalTrials.gov NCT05280054 · fetched Nov 12, 2026
- PH94B in the Treatment of Adjustment Disorder With AnxietyPHASE2 · COMPLETED · started Oct 12, 2021ClinicalTrials.gov NCT04404192 · fetched Nov 12, 2026
- Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)PHASE3 · TERMINATED · started Oct 1, 2021ClinicalTrials.gov NCT05030350 · fetched Nov 12, 2026
- PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2PHASE3 · TERMINATED · started Aug 30, 2021ClinicalTrials.gov NCT05011396 · fetched Nov 12, 2026
- PH94B Nasal Spray for Anxiety Induced by a Public Speaking ChallengePHASE3 · COMPLETED · started May 24, 2021ClinicalTrials.gov NCT04754802 · fetched Nov 12, 2026
- Electrophysiological Biomarkers of AV-101PHASE1_PHASE2 · COMPLETED · started Sep 1, 2018ClinicalTrials.gov NCT03583554 · fetched Nov 12, 2026
- AV-101 as Adjunct Antidepressant Therapy in Patients With Major DepressionPHASE2 · COMPLETED · started Mar 5, 2018ClinicalTrials.gov NCT03078322 · fetched Nov 12, 2026
SEC filings12
- 8-K · 8-KSEC EDGAR · filed Nov 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 30, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Oct 9, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 24, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 22, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 11, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 14, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jul 31, 2026 · fetched Nov 12, 2026